Dr. Stephen Lam discusses lung cancer nodules with study participant Mr. Chris Douglas. Photo credit: Chuck Russell, BC Cancer Agency
A Terry Fox Research Institute (TFRI)-led study has developed a new clinical risk calculator software that accurately classifies, nine out of ten times, which spots or lesions (nodules) are benign and malignant on an initial lung computed tomography (CT) scan among individuals at high risk for lung cancer.
The findings are expected to have immediate clinical impact worldwide among health professionals who currently diagnose and treat individuals at risk for or who are diagnosed with lung cancer, and provide new evidence for developing and improving lung-cancer screening programs. A total of 12,029 lung cancer nodules observed on CTs of 2,961 current and former smokers were examined in the population-based study.
In Canada, lung cancer kills over 20,000 Canadians annually. It is the primary cause of cancer deaths in Canada. One in 12 Canadians will receive a lung cancer diagnosis in his or her lifetime. With early detection, five-year survival rates can be over 70%.
The results were published in the Sept. 5th, 2013 issue of the New England Journal of Medicine (NEJM) and will have an immediate impact on clinical practice. “We already know that CT screening saves lives. Now, we have evidence that our model and risk calculator can accurately predict which abnormalities that show up on a first CT require further follow up, such as a repeat CT scan, a biopsy, or surgery, and which ones do not,”says co-principal investigator Dr. Stephen Lam, chair of BC’s Provincial Lung Tumour Group at the BC Cancer Agency and a professor of medicine at the University of British Columbia. “This is extremely good news for everyone – from the people who are high risk for developing lung cancer to the radiologists, respirologists and thoracic surgeons who detect and treat it. Currently, there are no Canadian guidelines for us to use in clinical practice.”
In countries where guidelines do exist, they largely relate to nodule size. The pan-Canadian team’s prediction model, developed by Brock University epidemiologist Dr. Martin Tammemägi, includes a risk calculator that considers several factors in addition to size: older age, female sex, family history of lung cancer, emphysema, location of the nodule in the upper lobe, part-solid nodule type, lower nodule count and spiculation (presence of sharp or needle-like points). “Reducing the number of needless tests and increasing rapid, intensive diagnostic workups in individuals with high-risk nodules are major goals of the model,” says Dr. Tammemägi.
The TFRI team used two sets of data to determine their findings, studying a total of 12,029 nodules from 2,961 persons – current and former smokers, aged 50-75, who had undergone low-dose CT screening. One set involved participants in the TFRI Pan-Canadian Early Detection of Lung Cancer Study from 2008 to 2010, where 1,871 persons with a total of 7,008 nodules (102 of which were malignant) were screened and followed. The other set involved 1,090 persons with 5,021 nodules (of which 42 were malignant) who took part in several lung cancer prevention trials conducted by the BC Cancer Agency during 2000-2010 and were funded through the U.S. National Cancer Institute (NCI). In the former study, participants were followed for an average of three years; in the latter, for an average of eight-and-a-half years.
Dr. Lam says the prediction model holds up even in cases where clinicians are faced with the toughest challenges; for example, deciding what to do when nodules are one centimeter (the approximate width of thumbnail blueberry) or smaller. While nodule size is one predictor of lung cancer, the largest nodule appearing on the CT was not necessarily cancerous. The pan-Canadian study team found that nodules located in the upper lobes of the lung carry an increased probability of cancer. In both data sets studied, researchers found that where cancer was present, fewer nodules were found. This model will simplify the work involved, especially for radiologists, in evaluating and assessing nodules on scans, as well as respirologists and thoracic surgeons who must make decisions about tests and treatment for their patients.
“Many jurisdictions throughout the world are now considering whether or how to best implement lung cancer screening. Studies like this one are key to answering important questions so decisions are most likely to result in good practice and planning, and ultimately benefit patients,” says Dr. Heather Bryant, vice-president, cancer control at the Canadian Partnership Against Cancer.
The Pan-Canadian study is funded by the TFRI, the research arm of the Terry Fox Foundation, and the Canadian Partnership Against Cancer. The BCCA study was supported by the United States Public Health Service National Cancer Institute.
Related Patient Story:
Pierre Lavigueur: http://www.tfri.ca/en/OurWork/patient-stories/pierre-lavigueur
St. John’s, Newfoundland
Halifax, Nova Scotia
Quebec City, Quebec
TFRI 2013-14 Annual Report : LUNG CANCER: Early detection increases survival, lowers treatment costs
Read the published research article in the New England Journals of Medicine
Watch a short video by NEJM about the lung study
Watch TFRI’s video with Dr. Lam and Mr. Douglas
Read our Terry Fox Lung Cancer Study backgrounder
BC Cancer Agency Lung Cancer Information
U.S. National Lung Screening Trial
Study Participant Testimonials:
Mr. Chris Douglas
Lung cancer survivor credits innovative lung cancer study with saving his life. Read his testimonial.
Mrs. Debi Laschelle
Ottawa resident receives excellent prognosis